LensAR, Inc. Company Profile
LensAR, Inc., is the leader in the development and commercialization of the next-generation laser and advanced 3D imaging technology for refractive cataract surgery. For more information, please visit www.lensar.com.
News Articles
FDA expands clearance for Lensar's cataract laser device
The FDA has given Lensar 510(k) clearance for its laser device to be used in making arcuate cuts in the cornea during catarac -More-
LensAR's next-gen cataract surgery device gets FDA OK
The FDA has granted LensAR 510(k) clearance for an advanced version of its cataract surgery laser device. -More-
Oxford Finance Provides $10 Million Senior Credit Facility to LensAR
ALEXANDRIA, Va., July 10, 2012 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announce...
FDA clearance for LENSAR Laser System
LENSAR Inc., developer of the next generation LENSAR Laser System™ for refractive cataract surgery, announced today that the company's laser system has received 510(k) clearance from the United Stat...
FDA clears LensAR Laser System for anterior capsulotomy
LensAR Inc., developer of the LensAR Laser System for cataract surgery, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the company'...
FDA clears LENSAR Laser System to perform corneal, arcuate incisions during cataract surgery
LENSAR Inc., developer of the next generation LENSAR Laser System™ for refractive cataract surgery, announced today that the company's laser system has received 510(k) clearance from the United Stat...
Sarasota, FL (PRWEB) December 16, 2012 The next generation of refractive cataract surgery reached another significant milestone when the United States Food and Drug Administration (FDA) issued clea...
Use of LENSAR's laser device for corneal incisions gets FDA OK
The FDA has given LENSAR expanded 510(k) clearance for use of its laser device in performing corneal incisions among patients -More- AssurX helps medical device companies meet tough FDA/regu...
Drugs and Medications
None
PubMed Articles
Intraocular lens short wavelength light filtering.
There is increasing interest in the effects of reactive oxygen species ('free radicals') in ageing, both in the body overall and specifically in the eye. Cataract and age-related macular degeneration...
Clinical Trials
None
Companies
LensAR, Inc., is the leader in the development and commercialization of the next-generation laser and advanced 3D imaging technology for refractive cataract surgery. For more info...
LensAR, Inc. is a leader in the development and commercialization of a next generation laser and advanced 3D imaging technology for refractive cataract surgery. For more informati...
More Information about "LensAR, Inc." on BioPortfolio
We have published hundreds of LensAR, Inc. news stories on BioPortfolio along with dozens of LensAR, Inc. Clinical Trials and PubMed Articles about LensAR, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of LensAR, Inc. Companies in our database. You can also find out about relevant LensAR, Inc. Drugs and Medications on this site too.
